10-Q: Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Terns Pharmaceuticals reported a net loss of $22.4 million for the first quarter of 2024, while highlighting progress in its clinical programs and a leadership transition.

Summary

• Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2024, reporting a net loss of $22.4 million, or $0.30 per share.
• The company's research and development expenses totaled $18.6 million, while general and administrative expenses were $6.9 million.
• Terns ended the quarter with $65.1 million in cash and cash equivalents and $175.6 million in marketable securities, totaling $240.7 million.
• The company believes its current cash position will fund operations into 2026.
• Key clinical programs include TERN-701, an allosteric BCR-ABL inhibitor, TERN-601, a GLP-1 receptor agonist, and TERN-501, a thyroid hormone receptor beta agonist.
• Terns is also advancing its TERN-800 series of GIPR modulators for obesity.
• The company highlighted positive pharmacokinetic data for TERN-701 and ongoing Phase 1 trials for TERN-601.
• A leadership transition was announced with Erin Quirk resigning as President and Head of Research & Development, effective May 7, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, this is expected for a clinical-stage biotech. The positive aspects include the cash runway, progress in clinical trials, and the potential of its novel drug candidates. The leadership transition and limited spending on TERN-501 are minor concerns.

Positives

• TERN-701 demonstrated favorable pharmacokinetic data, suggesting potential for food-agnostic dosing.
• The company's cash position is expected to fund operations into 2026.
• The Phase 1 trial for TERN-601 is progressing with no significant safety concerns reported to date.
• TERN-701 received Orphan Drug Designation, which could provide regulatory and commercial benefits.
• The company is actively pursuing the development of GIPR modulators for obesity, which could be combined with GLP-1 agonists.

Negatives

• The company reported a net loss of $22.4 million for the quarter.
• Terns has decided to limit spending on the TERN-501 program for MASH.
• The company is still in the clinical stage and has not generated revenue from product sales.
• There was a leadership transition with the resignation of the President and Head of Research & Development.

Risks

• The company is dependent on additional funding to support its operations.
• Clinical trials are subject to risks and uncertainties, and results may not be favorable.
• The company may not be able to obtain regulatory approvals for its product candidates.
• The company faces competition from other biopharmaceutical companies.
• The company's product candidates may not achieve commercial success even if approved.

Future Outlook

The company believes its existing cash and cash equivalents will be sufficient to fund its planned operating expenses and capital expenditure requirements into 2026, including key clinical data readouts from its lead programs in CML and obesity. Terns expects to report top-line 28-day weight loss data for TERN-601 in the second half of 2024 and interim data from initial cohorts in the CARDINAL trial for TERN-701 during the second half of 2024.

Management Comments

• The company is prioritizing its discovery efforts towards nominating a GIPR antagonist development candidate.
• The company continues to evaluate opportunities for TERN-501 in metabolic diseases.
• The company believes that its existing cash and cash equivalents will be sufficient to fund its planned operating expenses and capital expenditure requirements into 2026.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on oncology and metabolic diseases, particularly obesity. The development of GLP-1 agonists and GIPR modulators for obesity is a growing area of interest, and Terns is positioning itself to be a player in this space. The company's focus on allosteric BCR-ABL inhibitors for CML also aligns with the trend towards novel therapies in oncology.

Comparison to Industry Standards

• Terns' cash runway into 2026 is comparable to other clinical-stage biotech companies, but the specific burn rate and program progress will determine its relative strength.
• The reported R&D expenses of $18.6 million are within the expected range for a company with multiple clinical programs, but the efficiency of these expenditures will be a key factor.
• The company's focus on novel mechanisms like allosteric BCR-ABL inhibition and GIPR modulation positions it well against competitors using more established approaches.
• The company's decision to limit spending on TERN-501 for MASH reflects a strategic shift, which is not uncommon in the biotech industry when faced with regulatory and clinical development challenges.
• The company's ongoing Phase 1 trial for TERN-601 is in line with industry standards for early-stage clinical development of GLP-1 agonists.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the cash runway and clinical progress.
• Employees may be affected by the leadership transition and changes in program priorities.
• Customers (potential future patients) may be interested in the progress of clinical trials and the potential for new therapies.
• Suppliers and creditors may be reassured by the company's financial stability and cash position.

Next Steps

• The company expects interim data from initial cohorts in the CARDINAL trial for TERN-701 during the second half of 2024.
• Terns expects to report top-line 28-day weight loss data for TERN-601 in the second half of 2024.
• The company will continue to advance its TERN-800 series of GIPR modulators for obesity.
• The company will continue to evaluate opportunities for TERN-501 in metabolic diseases.

Key Dates

Keywords

biopharmaceutical, clinical-stage, oncology, obesity, metabolic diseases, TERN-701, TERN-601, TERN-501, GIPR modulators, GLP-1 agonists, BCR-ABL inhibitor, MASH, clinical trials, research and development, financial results